SLU-PP-332: The "Exercise in a Pill" That Isn't

Verdict

What Is SLU-PP-332?

Mechanism of Action: How ERR Agonists Work

What Are Estrogen-Related Receptors?

Estrogen-related receptors (ERRs) are orphan nuclear receptors — meaning no endogenous ligand (natural activating molecule) has been identified. Despite the name, ERRs are not estrogen receptors. They share structural similarity with estrogen receptors but do not bind estrogen and do not activate estrogenic pathways. ERRs control genes involved in energy metabolism, mitochondrial function, and oxidative phosphorylation. ERRalpha is the main driver of exercise-induced metabolic adaptation in skeletal muscle. Preclinical

The ERRalpha-DDIT4 Pathway

The key finding from the Burris lab is the link between ERRalpha activation and DDIT4 (DNA Damage Inducible Transcript 4). DDIT4 is a protein that is turned on after short bouts of aerobic exercise. SLU-PP-332 activates ERRalpha, which directly binds to DDIT4 gene regulatory regions and triggers the acute aerobic exercise gene program. That leads to downstream effects: mitochondrial biogenesis, more fatty acid oxidation, and a shift toward oxidative muscle fiber types.^[1]

graph TD
 A["SLU-PP-332
Synthetic Small Molecule"] --> B["ERRalpha Binding
EC50: 98 nM"]
 A --> B2["ERRbeta / ERRgamma
Lower affinity"]

 B --> C["DDIT4 Gene
Regulatory Region Binding"]
 C --> D["DDIT4 Protein
Expression Induced"]

 D --> E["Mitochondrial
Biogenesis"]
 D --> F["Fatty Acid
Oxidation Increase"]
 D --> G["Muscle Fiber Shift
Type IIa Oxidative"]

 H["Actual Exercise"] --> I["Thousands of Pathways
Across All Organ Systems"]
 I --> J["Cardiovascular Adaptation"]
 I --> K["Neuroplasticity"]
 I --> L["Immune Modulation"]
 I --> M["Bone Remodeling"]
 I --> N["Hormonal Regulation"]
 I --> O["ERR Pathway
(One of Thousands)"]

 style A fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 style B fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style B2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style C fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style D fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style E fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style F fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style G fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style H fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 style I fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style J fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style K fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style L fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style N fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style O fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 

The Animal Data: What Studies Actually Show

Four published studies make up the full evidence base for SLU-PP-332. All were done by the Burris lab. All used mice. All used intraperitoneal injection. None involved humans.

Study 1: Exercise Capacity and Muscle Fiber Shift

Billon C et al. "Synthetic ERRalpha/beta/gamma Agonist Induces an ERRalpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity." ACS Chemical Biology, 2023.^[1]

• Model: C57BL/6J mice
• Dose: 50 mg/kg i.p. twice daily
• Duration: 13 days (grip strength), 21 days (treadmill)
• Results: Mice ran approximately 70% longer and 45% further than controls. Increased grip strength. Shift toward Type IIa oxidative muscle fibers. Increased myosin IIA protein expression. Greater SDH staining (oxidative phenotype).
• Pharmacokinetics: At 30 mg/kg i.p., skeletal muscle concentration reached 0.6 microM vs plasma 0.2 microM at 2 hours post-dose.

Study 2: Metabolic Syndrome / Obesity

Billon C et al. "A Synthetic ERR Agonist Alleviates Metabolic Syndrome." J Pharmacol Exp Ther, 2024; 388(2):232-240.^[2]

• Model: Diet-induced obese (DIO) C57BL/6J mice and ob/ob mice
• Dose: 50 mg/kg i.p. twice daily (100 mg/kg/day total)
• Duration: 28 days (DIO mice), 12 days (ob/ob mice)
• Results: DIO mice: approximately 12% weight loss after 28 days. Fat mass gain substantially reduced (vehicle group gained ~5g, drug group gained less than 0.5g). 25% increase in fatty acid oxidation. Increased resting energy expenditure. Decreased respiratory exchange ratio within 2 hours of first dose. Increased muscle glucose uptake.
• Safety notes: "Only relatively minor changes in plasma cholesterol and liver enzyme levels" in chow-fed mice. No liver enzyme increases in DIO mice. No pancreatic histology changes.

Study 3: Aging Kidney

Billon C et al. "Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney." Am J Pathol, 2024.^[3]

• Model: 21-month-old C57BL/6J mice
• Dose: 25 mg/kg/day for 8 weeks
• Results: Reversed age-related albuminuria. Improved podocyte function. Reversed mitochondrial dysfunction. Reduced inflammatory cytokines (via cGAS-STING and STAT pathways). Decreased profibrotic markers (TGF-beta, PAI-1, Col IV).

Study 4: Heart Failure

Billon C et al. "Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function." Circulation, 2024.^[4]

• Model: Transaortic constriction (TAC)-induced heart failure mice
• Results: Improved ejection fraction. Ameliorated fibrosis. Increased survival. Did not affect cardiac hypertrophy. ERRgamma identified as the main mediator of cardioprotection.
• Note: SLU-PP-915 (a structurally distinct analog) was also tested in this study.

graph LR
 subgraph MOUSE["ALL STUDIES: MOUSE MODELS"]
 S1["Study 1
Exercise Capacity
50 mg/kg i.p. 2x daily
21 days"]
 S2["Study 2
Metabolic Syndrome
50 mg/kg i.p. 2x daily
28 days"]
 S3["Study 3
Aging Kidney
25 mg/kg/day
8 weeks"]
 S4["Study 4
Heart Failure
TAC model"]
 end

 subgraph ROUTE["ROUTE: ALL IP INJECTION"]
 R1["Intraperitoneal
Injection Only"]
 end

 subgraph HUMAN["HUMAN STUDIES"]
 H1["NONE"]
 end

 S1 --> R1
 S2 --> R1
 S3 --> R1
 S4 --> R1

 style MOUSE fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style ROUTE fill:#f4f4f5,stroke:#8a7d68,stroke-width:2px,color:#0a0a0a
 style HUMAN fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 style S1 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style S2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style S3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style S4 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style R1 fill:#f4f4f5,stroke:#8a7d68,stroke-width:1px,color:#0a0a0a
 style H1 fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 

The Dose Problem: 2,592 Capsules Per Day

This is the section that matters most. The mechanism of SLU-PP-332 is real. The mouse data is legitimate. But the supplements being sold have no relationship to what was studied. The math is simple.

Step 1: The Mouse Study Dose

The primary studies used 50 mg/kg intraperitoneally, twice a day — a total of 100 mg/kg/day. The route was intraperitoneal injection, which skips the gastrointestinal tract entirely.^[1],[2]

Step 2: FDA Body Surface Area Conversion (Mouse to Human)

The FDA-standard method for converting animal doses to human equivalent doses uses body surface area (BSA) scaling factors called Km values. This method is laid out in Reagan-Shaw et al. (2008).^[5]

Step 3: What Supplements Actually Contain

Typical SLU-PP-332 supplement capsules contain 250 mcg (0.25 mg) to 500 mcg (0.5 mg) per capsule.

Step 4: The Route-of-Administration Problem

The math above assumes the same bioavailability from injection and oral dosing. It is not the same. Every published study used intraperitoneal injection, which delivers the compound straight into the peritoneal cavity, skipping stomach acid, the GI tract, and the liver's first-pass metabolism. Oral bioavailability in mice is estimated at 40-50% — and there is zero data on human oral absorption.

The Complete Math Breakdown

graph LR
 subgraph STUDIED["WHAT WAS STUDIED"]
 A["Mouse Dose
100 mg/kg/day
IP Injection"]
 B["Human Equivalent
648 mg/day
(80 kg, FDA scaling)"]
 end

 subgraph SOLD["WHAT IS SOLD"]
 C["Supplement Capsule
0.25 mg/day
Oral"]
 end

 subgraph GAP["THE GAP"]
 D["2,592x Difference
(Before Oral
Bioavailability Adj.)"]
 E["~6,480x Difference
(After 40% Oral
Bioavailability Adj.)"]
 end

 A --> B
 B --> D
 C --> D
 D --> E

 style STUDIED fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style SOLD fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 style GAP fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 style A fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style B fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style C fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style D fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style E fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 

What Supplement Companies Don't Tell You

The "Peptide" Mislabeling

SLU-PP-332 is not a peptide. It is a synthetic small molecule. Calling it a peptide borrows unearned credibility from legitimate peptide research (BPC-157, TB-500, etc.). This is either ignorance of basic chemistry or deliberate marketing deception. There is no third option. Chemical Classification

The Route-of-Administration Problem

Every published study used intraperitoneal injection. IP injection delivers the compound straight into the peritoneal cavity, skipping the GI tract, liver first-pass metabolism, and stomach acid. Oral capsules face stomach acid, liver first-pass metabolism, and variable intestinal absorption. No study has shown equivalent effects from the oral route at any dose. On top of that, the compound reportedly degrades within 48 hours at room temperature — which raises questions about the stability of shelf-stable capsule products sitting in warehouses and on store shelves. Preclinical

The Anecdotal "Evidence" Problem

Influencer testimonials at supplement doses (250 mcg to 1 mg) are not evidence. At 0.04-0.15% of the human equivalent dose, any reported effects are placebo, confounded by other compounds in the stack, or coincidence. No controlled human observation exists at any dose. No Data

What the Experts Actually Say

What informed people in the enhancement community are saying about SLU-PP-332 is very different from what supplement companies present.

One expert in the biohacking space has called SLU-PP-332 "very promising" and compared it favorably to MOTS-c for mitochondrial support, explaining that ERRalpha acts as a "master switch that directly binds to and turns on genes for mitochondrial biogenesis, fat burning, and endurance." The same expert explicitly notes the insufficient safety data for human use. Expert-Discussed

This is a key point that virtually no supplement marketing addresses. If SLU-PP-332 is a prodrug — meaning it has to be metabolized into an active compound to produce its effects — then the metabolic pathway, the active metabolite, and the conversion efficiency in humans are all unknown. The compound that works in mice might not be the same compound doing the work. Unresolved

An Industry Expert Self-Experiment

At least one well-known figure in the enhancement community has publicly documented using SLU-PP-332 at 400 mg/day (100 mg four times a day) — raw powder sourced from China, not supplement capsules. This is important context for two reasons:

1. The dose actually approaches the allometrically scaled range. At 400 mg/day, the dose falls within the calculated human equivalent (320-810 mg/day depending on body weight and scaling method). This is a fundamentally different scenario from someone taking a 250mcg capsule.
2. The experimenter acknowledges the risk. The protocol has been described as a "whopping albeit animal dose extrapolated clinically approved dose for animals" — explicitly acknowledging its experimental nature.

Reports from this self-experiment include fast carbohydrate depletion ("the SLU is making me burn through carbohydrates quite fast"), difficulty keeping carbohydrate intake at 150 g/day, and the note that sourcing raw powder directly is "not cheap, but it's cheaper than doing the capsules." Expert-Discussed

A colleague of the experimenter has also said: "We got rat studies with the dose. It doesn't equate to a human dose. Much larger." And the experimenter has acknowledged: "There hasn't been any new data on it" — referring to the lack of new published studies since the original Burris lab work. Expert-Discussed

Risk Profile: The Unknown Unknowns

What Is Known From Animal Data

• No liver enzyme elevation in DIO mice at 100 mg/kg/day for 28 days^[2]
• No pancreatic histological changes^[2]
• "Minor changes" in cholesterol in chow-fed mice^[2]
• ob/ob mice only tolerated 12 days of treatment (vs. 28 for DIO mice) — reason not fully explained^[2]
• No cardiac hypertrophy observed in the heart failure model^[4]

What Is Completely Unknown

• Human metabolic pathway — no data
• Human metabolites — could produce toxic metabolites; no data
• Prodrug status — whether SLU-PP-332 is the active compound or a prodrug (raised by industry experts but unresolved)
• Long-term effects in any species — longest study was 8 weeks
• Interaction with human endocrine system — no data
• Interaction with other compounds — no data on interactions with AAS, GH, GLP-1 agonists, or any other compound
• Carcinogenicity / mutagenicity — never assessed
• Reproductive toxicity — never assessed
• CNS effects — never assessed
• Oral toxicity profile — all studies used IP injection; oral toxicity is unknown
• Individual variation in ERR expression and response — no data

For Physique Enhancement

What the Animal Data Suggests (Not Confirms)

• Increased fatty acid oxidation (~25% in mice)^[2]
• Shift toward oxidative muscle fibers (Type IIa)^[1]
• Reduced fat mass accumulation^[2]
• Increased resting energy expenditure^[2]

What It Does Not Do

• Build muscle tissue. SLU-PP-332 shifts muscle fiber type. It does not induce hypertrophy. There is no anabolic signaling pathway activated by ERR agonism.
• Replace training. Exercise activates thousands of pathways across every organ system. ERR agonism is one pathway within one system.
• Work at supplement doses. At 250mcg to 1mg, there is zero mechanistic basis to expect any effect on body composition. See Section 5 for the full dose math.

Practical Reality for Physique-Focused Users

At supplement doses (250 mcg to 1 mg), there is zero mechanistic basis to expect any effect on body composition. At the studied dose range (300-800+ mg/day), no safety data exists for human use. The compound was studied in sedentary, obese, or aged mice — not in trained, lean subjects. There is no data on interaction with anabolic compounds. Some bodybuilders have reportedly combined SLU-PP-332 with methylene blue and MOTS-c for mitochondrial support during cutting phases, but that is uncontrolled self-experimentation with no safety basis. Expert-Discussed

For Cognitive Enhancement

There are no studies — animal or human — looking at SLU-PP-332's effects on cognitive function. Zero. Any claims about nootropic or cognitive benefits are speculative extrapolation from mitochondrial function data. ERR activation may in theory support neuronal mitochondrial function, but that has not been tested. There is no published paper, no conference abstract, no preprint, and no registered study on SLU-PP-332 and cognition.

Do not buy SLU-PP-332 supplements for cognitive enhancement. There is no evidence base to support this use at any dose. No Data

Evidence Synthesis

What Is Established

1. SLU-PP-332 is a real, published, peer-reviewed research compound Confirmed
2. It activates ERR receptors, primarily ERRalpha (EC50: 98 nM)^[1]
3. In mice, at 50 mg/kg i.p. twice daily, it increases endurance, shifts muscle fiber type, reduces fat mass, and improves metabolic parameters^[1],[2]
4. The mechanism (ERRalpha to DDIT4 to exercise gene program) is well-characterized^[1]
5. Thomas Burris and colleagues at the University of Florida are legitimate researchers publishing in top-tier journals Confirmed

What Is Not Established

1. Any effect in humans at any dose No Data
2. Safety in humans at any dose No Data
3. Oral bioavailability in humans No Data
4. Whether supplement-range doses (250mcg to 1mg) have any biological activity in any species No Data
5. Long-term effects in any species No Data
6. Whether SLU-PP-332 is a prodrug or the active compound itself Unresolved

Conclusions

SLU-PP-332 is not snake oil. It is a real compound with real preclinical data behind it. The science published by Burris and colleagues is rigorous. The mechanism is well-characterized. The mouse data shows genuine effects on endurance, fat metabolism, and muscle fiber type. The researchers are legitimate academics publishing in Circulation, ACS Chemical Biology, and JPET. Preclinical

The problem is not the compound. The problem is the market that has formed around it.

Supplement companies are selling 250 mcg capsules of a compound that was studied at doses equivalent to 648-810 mg/day in humans, given by intraperitoneal injection. The supplement dose is 0.03-0.15% of the studied dose, given by a route that has never been tested for this compound. There is no human safety data, no human efficacy data, and no human pharmacokinetic data.

If SLU-PP-332 eventually enters human clinical trials and shows safety and efficacy at achievable doses, it could be a meaningful step forward in metabolic medicine. That day has not arrived. What has arrived is a supplement industry selling the hype of that possibility at prices that take advantage of consumer ignorance of basic pharmacology.

References

1. Billon C, et al. Synthetic ERRalpha/beta/gamma agonist induces an ERRalpha-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chem Biol. 2023;18(4):756-762. PubMed
2. Billon C, et al. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther. 2024;388(2):232-240. PubMed
3. Billon C, et al. Estrogen-related receptor agonism reverses mitochondrial dysfunction and inflammation in the aging kidney. Am J Pathol. 2024. PubMed
4. Billon C, et al. Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function. Circulation. 2024. PubMed
5. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659-661. PubMed

Frequently Asked Questions